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Abstract We conducted a pilot randomized controlled
trial to determine the feasibility and initial safety and
efﬁcacy of omega-3 fatty acids (1.3 g/day) for the treat-
ment of hyperactivity in 27 children ages 3–8 with Autism
spectrum disorder (ASD). After 12 weeks, hyperactivity, as
measured by the Aberrant Behavior Checklist, improved
2.7 (±4.8) points in the omega-3 group compared to 0.3
(±7.2) points in the placebo group (p = 0.40; effect
size = 0.38). Correlations were found between decreases
in ﬁve fatty acid levels and decreases in hyperactivity, and
the treatment was well tolerated. Although this pilot study
did not ﬁnd a statistically signiﬁcant beneﬁt from omega-3
fatty acids, the small sample size does not rule out small to
moderate beneﬁcial effects.
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Introduction
Omega-3 fatty acids are a commonly used complementary
and alternative medical (CAM) treatment for autism. In a
recent survey, 27.8% of families reported treating their
affected child with this supplement (Green et al. 2006). A
recently published systematic review (Bent et al. 2009)
identiﬁed only one, small randomized, placebo-controlled
trial that examined the efﬁcacy of omega-3 fatty acids for
autism. This study randomly assigned 13 children with
autism to 6 weeks of treatment with omega-3 fatty acids
(1.5 g per day) or an identical placebo, and found no sta-
tistically signiﬁcant improvements in the sub-scales of the
Aberrant Behavior Checklist (ABC) (Amminger et al.
2007). However, each of the ﬁve subscales (irritability,
social withdrawal, stereotypy, hyperactivity, and inappro-
priate speech) showed a non-signiﬁcant trend favoring the
omega-3 fatty acid treatment, with the largest improve-
ments noted in hyperactivity and stereotypy. Also, four
uncontrolled, open-label studies were identiﬁed (Bell et al.
2004; Meguid et al. 2008; Patrick and Salik 2005; Politi
et al. 2008), and three out of four reported various beneﬁts
related to core symptoms of autism, language and learning
skills, and general health.
Due to the common use of omega-3 fatty acids and
preliminary evidence from one small randomized con-
trolled trial suggesting a possible beneﬁt, we designed a
pilot study with a longer duration of treatment and a larger
Clinical Trial Registry Omega-3 Fatty Acids for Autism Treatment;
NCT00786799; http://www.clinicaltrials.gov/ct2/show/NCT00786799.
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DOI 10.1007/s10803-010-1078-8sample size to examine the feasibility and initial safety and
efﬁcacy of administering omega-3 fatty acids for the
treatment of hyperactivity and the core symptoms of ASD.
Methods
Participants
The study protocol and all procedures were approved by
the Committees on Human Research at the University of
California, Davis and the University of California, San
Francisco. The trial was registered prior to enrolling
patients at clinicaltrials.gov (NCT00786799) and took
place between November 5, 2008 and June 25, 2009.
Children between the ages of 3 and 8 with a diagnosis of
ASD were recruited from the outpatient autism clinic at the
MIND Institute (University of California, Davis). The
diagnosis of ASD was established using the Autism Diag-
nostic Observation Scale (ADOS), the Social Communi-
cation Questionnaire (SCQ) and by clinical review of the
DSM-IV TR criteria by an expert clinician (RLH). Children
were required to have a non-verbal IQ of 50 or more, be on a
stable medical regimen, and have a clinician rating of at
least moderate severity of autistic symptoms (Clinical
Global Impression Severity score of C4, range 0–7). Chil-
dren were excluded if they had a history of allergy to ﬁsh or
nuts, diabetes, a bleeding disorder, a seizure disorder, can-
cer, perinatal brain injury, other serious medical illness, or
current or prior use of omega-3 fatty acids.
Intervention
Children who satisﬁed all eligibility criteria were randomly
assigned to 12 weeks of treatment with omega-3 fatty acids
or an identical placebo. Omega-3 fatty acids were provided
as orange-ﬂavored pudding packets (Coromega
, Vista,
CA) containing 650 mg of omega-3 fatty acids, including
350 mg of eicosapentanoic acid (EPA) and 230 mg of
docosahexanoic acid (DHA), given twice daily for a daily
dose of 1.3 g of omega-3 fatty acids (and 1.1 g of
DHA ? EPA). Placebo packets had the same orange-ﬂa-
vored pudding with an identical appearance and taste, but
included safﬂower oil instead of the ﬁsh oil (omega-3 fatty
acids). Safﬂower oil was used because it is has a similar
texture and is comprised of fatty acids (but not omega-3
fatty acids), and this allowed for an examination of the
unique of effects of omega-3 fatty acids compared to ‘‘non-
omega-3’’ fatty acids. The orange ﬂavor in both the active
and placebo packets masked any ﬁshy taste.
Families were contacted by telephone 2 and 8 weeks
after randomization and had a brief clinical evaluation at
6 weeks. The children returned for a ﬁnal visit at week 12
for outcome assessment and study close-out. Compliance
was assessed by asking parents at the ﬁnal visit how often
children were able to take the study medication.
Objectives and Outcomes
The primary objective of this study was to examine the
feasibility and initial safety and efﬁcacy of administering
omega-3 fatty acids for the treatment of hyperactivity in
children with ASD.
Secondary outcomes of the study were designed to
examine changes in the core features of autism (commu-
nication problems, social difﬁculties, and repetitive/
restricted behavior) as well as biomarkers (serum free fatty
acids and cytokines) that might suggest a potential mech-
anism of action. Communication was assessed with the
Peabody Picture Vocabulary Test (which asks individuals
to point to a picture after hearing a word and is a standard
measure of receptive vocabulary) and the Expressive
Vocabulary Test (where the examiner points to a picture
and asks the individual to state the name, which is a
standard measure of expressive vocabulary). Social inter-
action was assessed with the Social Responsiveness Scale.
Behaviors were assessed with two parent-completed
questionnaires: (1) Aberrant Behavior Checklist (ABC),
and (2) Behavioral Assessment System for Children
(BASC). Global changes in the severity of autistic symp-
toms were evaluated by a clinician with the Clinical Global
Impression-Improvement (CGI-I) scale.
Randomization and Blinding
Eligible participants were randomized in equal proportions
using a computer-generated randomization list, which was
preparedbypersonswhowerenotinvolvedwiththestudy.All
participants, families, and study personnel (including clini-
cians and those performing baseline and outcome assess-
ments)wereblinded togroup assignmentfor the entire study.
Laboratory Methods
Cytokines were included as a possible biomarker because
evidence from prior studies suggests that omega-3 fatty
acids may have beneﬁcial effects through anti-inﬂamma-
tory actions (Simopoulos 2002). Cytokine analysis was
performed on plasma samples using multiplex assays
(Millipore) according to the manufacturer’s recommenda-
tion and read on a Luminex 100
TM platform. Lipid proﬁl-
ing was performed at Lipomics Technologies (West
Sacramento, CA) using a combination of chromatography
methods to quantitatively measure a range of lipid classes
and fatty acids within those classes, as previously described
(Wiest et al. 2009).
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123Statistical Methods
Because the study was a pilot study (and limited in size and
scope by available resources), the study was not designed
with sufﬁcient power to have a high likelihood of detecting
small to moderate changes in hyperactivity. Speciﬁcally,
the study was designed to recruit 24 subjects (12 subjects
per group) with a goal of detecting a 25% reduction in the
mean baseline hyperactivity subscale of the Aberrant
Behavior Checklist (ABC). A 25% reduction in the base-
line scores in the ABC has previously been used to deﬁne a
‘‘positive response’’ to therapy in autism (McCracken et al.
2002). We increased the target sample size to 27 to account
for possible withdrawals. Using an alpha level of 0.05, an
estimated standard deviation of the hyperactivity subscale
of 7.8 (derived from the prior pilot study), and a one-sided
test to detect a beneﬁcial response, the study was estimated
to have an 84% power to detect a 25% reduction in
hyperactivity. However, this power calculation relied on
both a high level of baseline hyperactivity and a large
change in hyperactivity (standardized effect size = 1.1), so
the study was designed to determine if use of omega-3 fatty
acids results in a large change in hyperactivity.
We compared baseline characteristics of the omega-3
and placebo groups using the student’s t-test for continuous
variables and chi-square tests for categorical variables. We
assessed the signiﬁcance of the difference in the changes
between groups using the Mann–Whitney test. Because this
was designed as an exploratory analysis, we did not adjust
p-values for multiple testing, which is consistent with prior
recommendations (Rothman 1990; Savitz and Olshan
1998; Thompson 1998). All reported p-values are two-
sided. If patients discontinued study medication, they were
asked to complete all outcome assessments at 12 weeks,
and they were analyzed in their assigned treatment group.
The funding organizations and the supplier of the
omega-3 and placebo study medication had no role in the
design or conduct of the study, the collection, management,
analysis, and interpretation of the data, or the preparation,
review, and approval of the manuscript.
Results
Patient Characteristics
Of 32 children who were screened for eligibility, 27 satis-
ﬁed all eligibility criteria and underwent randomization, 14
to omega-3 and 13 to placebo. The majority of enrolled
patients were male (13/14 in the omega-3 group and 11/13
in the placebo group).Figure 1shows reasons for exclusion,
loss to follow-up, and discontinuation of study medication.
Excluded (n=5) 
-IQ below threshold (n=3) 
-unable to complete baseline 
assessments (n=1) 
-did not meet diagnosis of autism
spectrum disorder (n=1) 
Assessed for eligibility (n=32) 
Randomized (n=27) 
Allocated to omega-3 (n=14) 
Received omega-3 (n=14) 
Allocated to placebo (n=13) 
Received placebo (n=13) 
Lost to follow-up (n=1, anxiety 
over blood draw, declined to 
return) 
Discontinued intervention (n=2, 1 
disliked taste, 1 increased self-
stimulatory behavior) 
Lost to follow-up (n=1, unable to 
tolerate study medication, declined 
to return) 
Discontinued intervention (n=4, 2 
disliked taste, 1 rash, 1 increased 
GI symptoms)
Analyzed (n=13)  Analyzed (n=12) 
Fig. 1 Flow diagram showing
distribution of participants at
each stage
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123One patient was lost to follow-up in the omega-3 group
after being unable to take the study medication (due to
disliking taste), and one patient was lost to follow-up in the
placebo group (due to anxiety over future blood draws).
Both patients declined to complete outcome measures,
leaving 13 analyzable patients in the omega-3 group and 12
in the placebo group. Compliance was reported to be per-
fect or nearly perfect for 9/13 analyzable patients (69%) in
the omega-3 group and 9/12 patients (75%) in the placebo
group. The baseline characteristics of the two treatment
groups were similar (Table 1).
Participants had a mean age of approximately 6 years
and a mean CGI-S score of 4.4, which is between the
categories of moderately ill (score of 4) and markedly ill
(score of 5).
Clinical Outcomes
Table 2 shows the primary outcome measure and all other
clinical outcome measures.
Hyperactivity as measured by the ABC improved 2.7
(±4.8) points in the omega-3 group compared to 0.3 (±7.2)
points in the placebo group, but this difference in change
scores was not statistically signiﬁcant (p = 0.40). There
was also a small, non-signiﬁcantly greater improvement in
hyperactivity as measured by the BASC (2.1 ± 6.3 in the
omega-3 group vs. 1.2 ± 5.8 in the placebo group,
p = 0.83). Most of the outcomes showed slightly larger
improvements in the omega-3 group compared to the pla-
cebo group, as indicated by the positive effect sizes which
range from 0.06 to 0.45, but none of these differences were
statistically signiﬁcant. Four outcomes—the irritability
subscale of the ABC, the Expressive Vocabulary Test, the
Social Responsiveness Scale, and the externalizing sub-
scale of the BASC showed greater improvements in the
placebo group (and therefore had negative effect sizes).
The CGI-I score, which reﬂects a clinician’s impression of
how the child’s overall symptom burden changed, was also
not different between groups. Two out of 13 children
(15%) in the omega-3 group and 3 out of 12 children (25%)
in the placebo group were rated as much improved or very
much improved on the CGI-I (p = 0.64).
Laboratory Outcomes
Changes in serum free fatty acids are shown in Table 3.
As expected, the percentage of serum omega-3 fatty
acids increased in the omega-3 group and decreased
Table 1 Baseline
characteristics
CGI-S clinical global
impression-severity,
ABC aberrant behavior
checklist, PPVT peabody
picture vocabulary test,
EVT expressive vocabulary test,
SRS social responsiveness scale,
BASC behavioral assessment
system for children
Characteristic Omega-3 group
(n = 13)
mean (SD)
Placebo (n = 12)
mean (SD)
Total (n = 25)
mean (SD)
p-value (placebo
vs. omega-3)
Age (months) 70.2 (22) 69.8 (17) 70.0 (20) 0.89
CGI-S 4.6 (0.5) 4.2 (0.4) 4.4 (0.5) 0.03
Stanford Binet—IQ 77.5 (27) 77.5 (17) 77.5 (23) 0.59
ABC—total 40.6 (30) 51.8 (24) 46.0 (28) 0.31
ABC—hyperactivity 16.8 (13) 20.3 (8) 18.4 (11) 0.37
ABC—irritability 10.1 (10) 12.0 (7) 11.0 (8) 0.35
ABC—stereotypy 2.8 (3) 6.0 (5) 4.3 (4) 0.12
ABC—lethargy 7.7 (7) 8.3 (7) 8.0 (7) 0.80
ABC—IS 3.3 (3) 5.2 (3) 4.2 (3) 0.16
PPVT 72.2 (28) 85.5 (12) 78.6 (23) 0.11
EVT 70.8 (33) 86.4 (14) 78.3 (26) 0.33
SRS 76.9 (11) 79.0 (8) 77.9 (10) 0.76
BASC—externalizing 53.8 (13) 66.3 (25) 59.8 (20) 0.08
BASC—internalizing 43.3 (10) 50.1 (9) 46.3 (10) 0.14
BASC—behavioral 60.9 (14) 65.4 (3) 63.0 (11) 0.31
BASC—adaptive skill 29.8 (9) 31.9 (9) 30.7 (9) 0.58
BASC-hyperactivity 61.8 (17) 64.6 (7) 63.1 (13) 0.35
Gastrointestinal symptoms 2/13 (15%) 1/12 (8%) 3/25 (12%) 1.00
Frequent infections 2/13 (15%) 1/12 (8%) 3/25 (12%) 1.00
Food allergy 1/13 (8%) 2/12 (17%) 3/25 (12%) 0.58
Regression 3/13 (23%) 2/12 (17%) 5/25 (20%) 1.00
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123slightly in the placebo group (?2.5% vs. -0.1%,
p = 0.01). Both DHA and EPA also showed statistically
signiﬁcant increases in the treatment group compared to the
placebo group. Nine individual fatty acid levels and four of
the eight class percentages (% monounsaturated, % poly-
unsaturated, % omega-3, and % omega-9) also showed
statistically signiﬁcant differences in changes over the
course of the study, suggesting that omega-3 supplemen-
tation for 12 weeks led to marked differences in fatty acid
proﬁles.
Changes in cytokine levels (pg/ml) are shown in
Table 4.
Of 29 cytokines measured, only one (TNFa)r e v e a l e da
statisticallysigniﬁcantdifferenceinthemeanchangeoverthe
course of the study between groups. Interestingly, this cyto-
kineincreasedintheomega-3group(by1.3 ± 2.5 pg/ml)and
decreased in the placebo group (by -0.9 ± 2.1 pg/ml,
p = 0.023).
Weexaminedcorrelationsbetweenchangesineachofthe
measured laboratory values (free fatty acids and cytokines)
andchangesinhyperactivityamongallstudyparticipants.A
change in one cytokine level (IL-2) showed a correlation
with change in hyperactivity (as IL-2 increased, hyperac-
tivity decreased; Spearman rank -0.44, p = 0.045). Five
free fatty acids showed strong correlations such that
decreases in 18:1n9, 22:1n9, dm18:1n9, % monounsatured,
and%omega-9fattyacidswereassociatedwithdecreasesin
hyperactivity (Spearman coefﬁcients are respectively 0.48,
0.59, 0.47, 0.48, and 0.46 with p-values 0.02, 0.003, 0.02,
0.02, and 0.03).
We also examined whether baseline levels of free fatty
acids were correlated with changes in hyperactivity
among patients in the omega-3 group, with the goal of
identifying predictors of response to therapy. The baseline
level of ﬁve fatty acids showed statistically signiﬁcant
correlations with changes in hyperactivity among patients
in the omega-3 group. For two of these fatty acids, 22:0
and 24:0, lower baseline levels were correlated with
reductions in hyperactivity (Spearman coefﬁcients of 0.73
and 0.72 and p-values of 0.007 and 0.009 respectively).
For three of these fatty acids (20:2n6, 22:2n6, and
18:3n3), higher baseline levels were associated with
reductions in hyperactivity (Spearman coefﬁcients of
-0.79, -0.65, and -0.64 with p-values of 0.002, 0.03,
and 0.03, respectively).
Side Effects
No serious adverse events were reported during the study,
and there was no difference in the number of reported non-
Table 2 Changes in primary and secondary outcome measures
Omega-3
change (SD)
N = 13
Placebo
change (SD)
n = 12
Difference in change
between groups (SD)
95% conﬁdence
interval
Standardized
effect size
a
p-value
Primary outcome measure
ABC hyperactivity 2.7 (4.8) 0.3 (7.2) 2.3 (6.1) -3.0 to 7.4 0.38 0.40
Secondary outcome measures
ABC
Irritability 0.8 (4.7) 1.1 (5.1) -0.3 (4.9) -4.6 to 3.7 -0.07 0.95
Stereotypy 0.7 (1.2) 0.3 (2.6) 0.4 (2.1) -1.3 to 2.1 0.20 0.36
Lethargy 2.7 (4.8) 1.9 (5.7) 0.8 (5.3) -3.7 to 5.2 0.16 0.54
Inappropriate speech 1.2 (2.0) 0.7 (2.3) 0.5 (2.2) -1.4 to 2.2 0.23 0.79
PPVT 2.7 (11.6) 1.9 (12.4) 0.8 (12.0) -9.1 to 10.7 0.06 0.60
EVT 2.2 (7.6) 5.8 (5.7) -3.7 (6.7) -9.3 to 1.9 -0.55 0.18
SRS -0.9 (6.5) 1.7 (7.2) -2.6 (6.8) -8.7 to 3.5 -0.39 0.38
BASC
Externalizing 0.1 (6.7) 6.6 (30.4) -6.5 (22.0) -26.3 to 11.1 -0.30 0.45
Internalizing 0.3 (6.6) -2.9 (7.6) 3.2 (7.1) -4.0 to 8.7 0.45 0.33
Behavioral -1.1 (6.1) -2.0 (4.9) 0.9 (5.6) -4.8 to 5.7 0.16 0.97
Adaptive skill 1.8 (6.8) 0.8 (7.1) 1.0 (6.9) -5.7 to 6.7 0.14 0.84
Hyperactivity 2.1 (6.3) 1.2 (5.8) 0.9 (6.1) -4.5 to 6.0 0.15 0.83
All changes are shown as positive when there was an improvement in the score and negative when there was a worsening of the score
ABC aberrant behavior checklist, PPVT peabody picture vocabulary test, EVT expressive vocabulary test, SRS social responsiveness scale, BASC
behavioral assessment system for children
a Effect sizes are positive when the change in omega-3 is greater (more beneﬁcial or less harmful) than the change in placebo
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123serious adverse events in the two treatment groups. Five of
fourteen patients reported adverse events in the omega-3
group (2 rashes, 1 upper respiratory infection, 1 nose bleed,
1 increased GI symptoms); four of thirteen patients
reported adverse events in the placebo group (3 increased
hyperactivity, 1 increased self-stimulatory behavior).
Adequacy of Blinding
Among families who used at least some study medication
and responded to the question, ‘‘do you think your child
was taking omega-3 fatty acids or placebo?’’ at the end of
the study, there was no statistical difference in the
Table 3 Free fatty acid
changes
Fatty acids are described by
their lipid number, which takes
the form C:D, where C is the
number of carbon atoms in the
fatty acid and D is the number
of double bonds in the fatty
acid. All units are expressed as
moles of fatty acid as a
percentage of total moles fatty
acid in the lipid class
dm dimethyl, EPA
eicosapentanoic acid, DHA
docosahexanoic acid
Free fatty acid Baseline SD Mean change
omega-3
SD Mean change
Placebo
SD p-value
14:0 1.27 0.8 -0.10 0.8 -0.18 0.8 0.82
15:0 0.23 0.1 0.01 0.1 -0.03 0.1 0.02
16:0 20.64 2.6 -1.20 2.4 0.08 2.2 0.22
18:0 8.07 0.7 0.15 0.6 -0.17 0.6 0.22
20:0 0.18 0.0 0.02 0.0 -0.02 0.1 0.10
22:0 0.41 0.2 0.06 0.1 -0.10 0.2 0.02
24:0 0.37 0.1 0.06 0.1 -0.09 0.1 0.01
14:1n5 0.09 0.1 -0.03 0.1 0.00 0.1 0.45
16:1n7 1.29 0.7 -0.37 0.8 0.03 0.5 0.22
18:1n7 1.19 0.2 -0.05 0.1 0.07 0.2 0.20
18:1n9 18.90 3.6 -2.43 4.6 1.44 1.9 0.01
20:1n9 0.17 0.1 -0.03 0.1 0.00 0.1 0.32
20:3n9 0.09 0.0 -0.02 0.0 -0.01 0.0 0.42
22:1n9 0.03 0.0 0.00 0.0 0.00 0.0 0.35
24:1n9 0.36 0.1 0.06 0.1 -0.02 0.1 0.15
18:2n6 33.72 4.8 2.04 5.5 -0.66 4.4 0.15
18:3n6 0.57 0.3 -0.15 0.4 -0.06 0.3 0.64
20:2n6 0.32 0.1 -0.03 0.1 -0.03 0.1 0.56
20:3n6 1.54 0.4 -0.30 0.6 -0.04 0.3 0.30
20:4n6 6.30 1.5 -0.28 1.5 -0.10 0.9 0.38
22:2n6 0.01 0.0 0.00 0.0 0.00 0.0 0.49
22:4n6 0.25 0.1 -0.06 0.1 0.00 0.0 0.03
22:5n6 0.22 0.1 -0.08 0.1 -0.01 0.0 0.01
18:3n3 0.78 0.4 -0.02 0.3 -0.02 0.3 0.95
18:4n3 0.04 0.0 -0.01 0.0 -0.01 0.0 0.81
20:4n3 0.07 0.0 -0.01 0.0 -0.02 0.0 0.82
20:5n3 (EPA) 0.43 0.6 0.99 1.3 -0.04 0.1 0.03
22:5n3 0.43 0.1 0.23 0.2 -0.01 0.1 0.003
22:6n3 (DHA) 1.34 0.8 1.36 1.4 -0.01 0.2 0.02
dm16:0 0.35 0.1 0.07 0.1 -0.01 0.0 0.18
dm18:0 0.23 0.1 0.08 0.1 0.00 0.1 0.10
dm18:1n7 0.02 0.0 0.01 0.0 0.00 0.0 0.45
dm18:1n9 0.11 0.0 0.00 0.1 0.01 0.0 0.95
% Saturated 31.75 3.3 -0.84 3.0 -0.51 2.8 0.60
% Monounsaturated 22.15 4.0 -2.83 5.0 1.5 2.3 0.007
% Polyunsaturated 46.09 5.4 3.67 6.6 -1.01 3.7 0.04
% Omega-3 3.08 1.4 2.54 2.8 -0.10 0.3 0.01
% Omega-6 42.92 5.2 1.15 5.9 -0.90 3.7 0.30
% Omega-7 2.47 0.7 -0.42 0.9 0.10 0.6 0.15
% Omega-9 19.55 3.6 -2.42 4.5 1.41 2.0 0.01
% Dimethyl 0.70 0.2 0.15 0.3 0.0 0.1 0.09
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123percentage of families who believed they had been given
omega-3 (7/11 or 64% in the placebo group vs. 4/10 or
40% in the omega-3 group, p = 0.39).
Discussion
In this pilot study, we found that treatment with omega-3
fatty acids did not lead to a statistically signiﬁcant
improvement in hyperactivity in children with ASD.
Although non-signiﬁcant, there was a greater reduction in
hyperactivity in the treatment vs. the placebo group in this
study, which corresponds to a standardized effect size of
0.38 and is considered to be a small treatment effect
(McDowell and Newell 1996). The interpretation of these
ﬁndings is difﬁcult and highlights the limitations of pilot
studies and the inherent challenges of studying the efﬁcacy
of CAM therapies for ASD. The most conservative inter-
pretation of this study is that we found no statistically
signiﬁcant treatment effect, and since the study was
designed with enough power to ﬁnd a large treatment effect
(84% power to identify a treatment effect size = 1.1), we
might conclude that omega-3 fatty acids do not produce a
large beneﬁcial effect for reducing hyperactivity, at least
among children with ASD who have mild-to-moderate
baseline levels of hyperactivity.
However, because pilot studies generally have small
sample sizes, the resulting effect estimates are unreliable
and therefore decisions regarding the need for future, larger
studies should not be based on the results of pilot studies
alone (Kraemer et al. 2006). Small pilot studies are not
designed to provide deﬁnitive scientiﬁc evidence regarding
efﬁcacy; their primary purpose is to prepare for larger
studies by examining issues such as the availability of
eligible subjects, the recruitment methods, the procedures
for staff training, the tolerability of treatment, and the
collection and storage of data (Kraemer et al. 2006). This
presents a difﬁcult dilemma for the scientiﬁc investigation
Table 4 Laboratory values:
cytokines
All units are expressed in
picograms/milliliter
TGF tumor growth factor,
BDNF brain-derived
neurotrophic factor,
IL interleukin, IP-10 10 kDa
interferon-gamma-induced
protein, MCP-1 monocyte
chemotactic protein-1, MIP
macrophage inﬂammatory
protein, TNF tumor necrosis
factor, INF interferon, GM-CSF
granulocyte-macrophage
colony-stimulating factor,
G-CSF granulocyte colony-
stimulating factor
Cytokines Baseline
mean
SD Omega-3 mean
change
SD Placebo mean
change
SD p-value
TGF-b-1 12242.07 7673.9 -3608.93 10725.9 4606.84 10992.2 0.11
TGF-b-2 12674.20 7594.9 -3354.03 11186.9 4202.95 9947.3 0.11
BDNF 864.75 535.3 -120.00 768.9 -176.64 434.8 0.77
IL-1a 218.75 288.1 -35.34 557.0 174.92 528.7 0.72
IL-1b 2.27 2.6 -0.15 1.0 0.11 1.1 0.59
IL-2 2.44 3.0 6.24 16.3 0.28 2.9 0.25
IL-3 4.90 0.0 0.72 2.5 0.00 0.0 0.41
IL-4 7.20 11.9 -2.19 7.7 -0.16 3.1 0.57
IL-5 2.04 3.6 -1.14 5.8 0.57 1.5 0.52
IL-6 6.83 11.1 3.19 25.7 7.68 24.8 0.97
IL-7 9.06 19.3 1.82 14.3 1.53 13.5 0.49
IL-8 5.90 7.8 6.45 14.1 -0.57 10.2 0.12
IL-10 6.20 2.8 2.23 15.4 6.78 16.4 0.28
IL-12(p40) 83.76 104.5 14.32 80.5 -6.85 62.1 0.72
IL-12(p70) 4.73 4.6 24.61 74.3 -0.50 9.4 0.19
IL-13 1.55 1.5 33.67 116.8 -0.15 2.0 0.57
IL-15 2.73 1.3 8.82 31.4 -0.28 0.9 0.57
IL-17 8.64 17.7 13.91 37.9 -5.22 26.0 0.20
IP-10 346.73 313.2 63.52 865.6 125.25 913.6 0.92
MCP-1 337.82 76.6 -30.84 123.8 -27.76 179.2 0.87
MIP-1a 46.92 56.1 16.75 68.9 -16.18 51.0 0.45
MIP-1b 27.06 14.7 8.39 24.9 1.03 17.5 0.34
TNF-a 5.21 1.2 1.34 2.5 -0.89 2.1 0.023
TNF-b 3.51 2.9 5.25 19.7 0.34 3.2 0.73
INF-c 11.90 19.1 11.92 32.1 -0.83 19.9 1.00
INF-a2 218.75 288.1 -22.66 557.9 174.92 528.7 0.97
GM-CSF 54.16 63.5 20.29 66.4 15.18 89.7 0.92
G-CSF 58.67 40.6 -18.40 53.2 25.52 102.0 0.31
Eotaxin 83.73 36.0 0.92 17.7 -33.43 47.8 0.060
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123of the efﬁcacy of CAM therapies for ASD. There is little or
no high-quality scientiﬁc evidence evaluating the safety
and efﬁcacy of most CAM therapies for ASD even though
these therapies are used by as much as 95% of affected
children. Because there is limited scientiﬁc evidence for
the efﬁcacy of most of these CAM therapies, it is difﬁcult
to justify or obtain funding to conduct a large, randomized
controlled trial that would provide deﬁnitive scientiﬁc
evidence regarding efﬁcacy. Therefore, most clinical
investigations of CAM therapies can only attract small
amounts of funding to conduct small pilot studies, and
these studies are often (incorrectly) used as the basis for
‘‘triage’’ or decision making regarding the need for future,
larger studies. It is a difﬁcult cycle: there is no evidence, so
only funding for small studies can be obtained, and these
studies do not provide enough evidence to make decisions
regarding future studies. So, the question remains, how
does one decide whether to conduct larger studies if effect
estimates from pilot studies are inaccurate and insufﬁcient?
The answer to this question is complex and involves
considerations of other evidence of efﬁcacy of the agent in
question, examination of a plausible mechanism of action,
the severity of the clinical problem and the availability of
other effective treatments. In the case of omega-3 fatty
acids for the treatment of hyperactivity for ASD, only one
prior, small, pilot randomized controlled trial has been
conducted. This study found a non-signiﬁcant trend of a
greater reduction in hyperactivity in patients in the omega-
3 group compared to the placebo group (p = 0.098)
(Amminger et al. 2007). In that study, the standardized
effect size for the improvement in hyperactivity was 0.71,
about twice the size of the effect estimate observed in the
current study (0.38), and this difference is possibly due to
the fact that patients in the prior study had higher baseline
levels of hyperactivity (baseline ABC hyperactivity score
of 33.3 in the omega-3 group of the prior study compared
to a baseline score of 16.8 in the current study). It is also
possible that the observed effect size in the prior study was
not due to treatment with omega-3 fatty acids, but merely
due to the fact that patients in the omega-3 group had
higher baseline hyperactivity scores than patients in the
placebo group (Gilbert 2008). However, the observation
that both the current study and the one prior randomized
controlled trial found an effect estimate in the same
direction may provide some limited evidence that omega-3
fatty acids could have a small beneﬁcial effect.
Other relevant evidence regarding the potential efﬁcacy
of omega-3 fatty acids comes from studies of this supple-
ment in other psychiatric disorders. A recent systematic
review examining the evidence for efﬁcacy of omega-3
fatty acids for mental health disorders (conducted by the
Agency for Healthcare Research and Quality) noted many
potential mechanisms of action of omega-3 fatty acids
which might contribute to normal brain development and
function (Schachter et al. 2005). However, there were very
few high-quality randomized controlled trials examining
efﬁcacy, leading the authors to conclude that there was
insufﬁcient evidence to determine whether omega-3 fatty
acids are effective for depression, and only limited evi-
dence to suggest that they might be effective for the
treatment of schizophrenia. A separate systematic review
identiﬁed 11 small randomized controlled trials of omega-3
fatty acids in patients with attention-deﬁcit-hyperactivity
disorder (ADHD) and found that the overall quality of
evidence was poor, preventing deﬁnitive conclusions
regarding efﬁcacy (Raz and Gabis 2009). A recent ran-
domized, placebo-controlled trial in 81 young adults who
were high-risk for developing psychosis found that patients
treated with 12 weeks of omega-3 fatty acids had a much
lower risk of progression to a psychotic disorder (4.9%
progressed in the omega-3 group vs. 27.5% in the placebo
group) (Amminger et al. 2010). Overall, the prior evidence
for efﬁcacy of omega-3 fatty acids in other mental disor-
ders is limited, though there are clearly several plausible
biological mechanisms of action and some clinical trial
evidence to support a possible beneﬁcial effect in certain
conditions.
If omega-3 fatty acids are effective for reducing hyper-
activity in ASD, the mechanism of action is not clear, but
the laboratory measurements in this study suggest some
possible lines of inquiry. As expected, there were differ-
ences in the changes of fatty acid proﬁles in treated vs.
placebo patients, most notably with an increase in omega-3
fatty acids among treated patients. Also, ﬁve fatty acid
measurements showed correlations with changes in hyper-
activity, suggesting that, at least for some individuals, a
change in fatty acid proﬁle may be necessary to elicit a
positive behavioral response. Two of three previous studies
reported lower levels of omega-3 fatty acids in children
with autism compared to controls (Bell et al. 2004; Bu et al.
2006; Vancassel et al. 2001), but this is the ﬁrst study to
show that changes in speciﬁc fatty acid levels correlate with
changes in a behavioral outcome. Similarly, baseline levels
of ﬁve of the measured fatty acids were correlated with a
reduction in hyperactivity among treated patients. Future
research is needed to determine if these speciﬁc fatty acids
might be useful for predicting response to therapy.
The primary limitation of this study is the small sample
size, which (as noted above) results in a limited power to
detect small to moderate treatment effects. The study was
also limited by the relatively mild level of hyperactivity in
both the placebo and omega-3 treatment groups. The goal
of the study was to examine the effect of omega-3 fatty
acids in unselected children with ASD, where the preva-
lence of hyperactivity is already quite high. For example, in
a survey of 487 children with ASD, the prevalence of
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123symptoms related to hyperactivity was very high: difﬁculty
concentrating (49%); easily distracted (60%); ﬁdgets,
wiggles, and squirms (42%); overactive (41%); and short
attention span (54%) (Lecavalier 2006). However, because
our enrolled population had only mildly elevated levels of
hyperactivity, future studies should consider setting a
threshold level of hyperactivity as an inclusion criterion to
ensure a greater level of severity and therefore more
opportunity to detect improvement in hyperactivity with
treatment. A suitable goal might be to select children with
at least a one standard deviation increase in a baseline
measure of hyperactivity such as the Aberrant Behavior
Checklist hyperactivity subscale.
In summary, this pilot study revealed no statistically
signiﬁcant effects of omega-3 fatty acids on hyperactivity
or the core symptoms of autism after 12 weeks of treat-
ment. However, because the study was a pilot study with a
relatively small sample size, the estimate of treatment
effect is unreliable, and this study alone does not provide
deﬁnitive evidence regarding the efﬁcacy of omega-3 fatty
acids. Based on this study and the scientiﬁc literature to
date, we believe it is not possible to determine whether
omega-3 fatty acids are effective for treating hyperactivity
in ASD. However, there are a number of compelling rea-
sons to suggest that a larger study is indicated. Both the
current study and one prior study did ﬁnd small, non-sig-
niﬁcant improvements in hyperactivity in the omega-3
group compared to the placebo group. Also, in the current
study, changes in hyperactivity were correlated with
changes in certain fatty acids levels, suggesting a possible
mechanism of action. The treatment was well-tolerated and
resulted in no serious side effects. Omega-3 fatty acids are
widely used, relatively inexpensive, and have substantial
evidence establishing safety in children. Further, hyperac-
tivity is a very common problem among children with
ASD. A recent survey of 479 parents of children with ASD
found that 46% of children had used stimulant medications
by adolescence, suggesting that almost half of children
with ASD have hyperactivity that is troubling enough to
require a trial of stimulant medication (Goin-Kochel et al.
2007). Current drug treatment of hyperactivity in children
with ASD has limited efﬁcacy and is associated with sig-
niﬁcant side effects (Aman and Langworthy 2000). In order
to deﬁnitively determine if omega-3 fatty acids are a useful
treatment option for hyperactivity in children with ASD, a
larger randomized controlled trial with sufﬁcient power to
identify a clinically relevant beneﬁt is needed.
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